Stroke accounts for 143 million disability-adjusted life years worldwide. While thrombectomy can raise functional independence rates above 70% in trials, real-world data shows only 6.8% of acute ischemic stroke patients receive IV alteplase. These figures highlight a persistent gap between potential and delivered care.
Key Takeaways
- The Global Burden of Disease 2019 estimates stroke accounted for 143.2 million DALYs globally, translating to substantial economic burden
- In the US Medicare population, total spending for stroke is in the tens of billions annually (reported Medicare analysis indicates ~$40+ billion depending on year definition)
- The WHO states that stroke is a leading cause of death and disability worldwide
- Among 6,000+ patients included in the PROGRESS trial, blood pressure lowering reduced stroke by about 28% (relative risk reduction for stroke)
- In a meta-analysis, statin therapy reduced stroke by 21% per 1.0 mmol/L reduction in LDL cholesterol
- Atrial fibrillation is present in about 25% of ischemic strokes in older adults (proportion cited across population studies)
- Mechanical thrombectomy increases the odds of functional independence compared with medical therapy alone (pooled trials show benefit; commonly reported ~2x higher odds)
- In the MR CLEAN trial, 32.6% achieved functional independence (mRS 0-2) with thrombectomy vs 19.1% with usual care
- In Get With The Guidelines–Stroke (GWTG-Stroke) registry, IV alteplase was administered to 6.8% of acute ischemic stroke patients (2012–2020 reporting in registry publications)
- In GWTG-Stroke, overall achievement of key stroke measures (e.g., VTE prophylaxis, aspirin by end of day 2, smoking cessation counseling) ranges across domains but is commonly reported around 70%+ for multiple measures
- The proportion of patients receiving mechanical thrombectomy in US hospitals treating ischemic stroke with large vessel occlusion increased substantially over time, reaching about 10%+ of ischemic stroke admissions in recent registry data
- 7.5 million new strokes occur globally every year, according to GBD 2019 estimates
- Stroke accounts for 6.5% of all deaths globally (GBD 2019 estimate; cause-of-death share)
- 51% of acute ischemic stroke patients in a 2020 European register received intravenous thrombolysis (IVT) within guideline-based time windows
- In the Global Burden of Disease framework, stroke accounts for 15.7% of total years lived with disability (YLDs) globally (GBD 2019 cause share)
Stroke prevention and faster treatments like thrombectomy and thrombolysis can greatly improve outcomes and reduce disability worldwide.
Related reading
01 · Category
Market, Costs & Resources8 stats
01
The Global Burden of Disease 2019 estimates stroke accounted for 143.2 million DALYs globally, translating to substantial economic burden
02
In the US Medicare population, total spending for stroke is in the tens of billions annually (reported Medicare analysis indicates ~$40+ billion depending on year definition)
03
The WHO states that stroke is a leading cause of death and disability worldwide
04
The American Stroke Association estimates stroke-related costs in the US are about $50.6 billion per year (medical costs and productivity losses)
05
The American Stroke Association estimates medical costs for stroke in the US are about $26.9 billion per year (direct costs)
06
The American Stroke Association estimates productivity losses due to stroke in the US are about $23.7 billion per year
07
A 2023 systematic review reports that out-of-pocket costs for stroke caregivers can be substantial, with reported median caregiver out-of-pocket expenses frequently exceeding $1000per year
08
In a study of stroke rehabilitation costs, inpatient rehabilitation averages several thousand US dollars per episode (reported median/mean values in the study)
Interpretation
Market, Costs & Resources Interpretation
From a Market, Costs & Resources perspective, stroke imposes a massive and split financial burden, with global health losses of 143.2 million DALYs and US annual costs around $50.6 billion, including $26.9 billion in direct medical spending and $23.7 billion in productivity losses, often compounded by caregiver out-of-pocket expenses that can exceed $1,000 per year.
02 · Category
Risk Factors & Prevention2 stats
01
Among 6,000+ patients included in the PROGRESS trial, blood pressure lowering reduced stroke by about 28% (relative risk reduction for stroke)
02
In a meta-analysis, statin therapy reduced stroke by 21% per 1.0 mmol/L reduction in LDL cholesterol
Interpretation
Risk Factors & Prevention Interpretation
In the Risk Factors and Prevention category, the evidence shows that lowering blood pressure can cut stroke risk by about 28% in the PROGRESS trial and that statins further reduce stroke by 21% for every 1.0 mmol/L drop in LDL cholesterol.
03 · Category
Diagnosis, Treatment & Outcomes9 stats
01
Atrial fibrillation is present in about 25% of ischemic strokes in older adults (proportion cited across population studies)
02
Mechanical thrombectomy increases the odds of functional independence compared with medical therapy alone (pooled trials show benefit; commonly reported ~2x higher odds)
03
In the MR CLEAN trial, 32.6% achieved functional independence (mRS 0-2) with thrombectomy vs 19.1% with usual care
04
In the ESCAPE trial, functional independence (mRS 0-2 at 90 days) occurred in 53.0% with thrombectomy vs 29.3% with control
05
In the SWIFT PRIME trial, functional independence (mRS 0-2 at 90 days) was 60.2% with thrombectomy vs 43.5% with control
06
In the EXTEND-IA trial, functional independence (mRS 0-2 at 90 days) was 71.1% with thrombectomy vs 40.4% with control
07
In the HERMES meta-analysis (five thrombectomy trials), thrombectomy increased likelihood of functional independence (mRS 0-2) (adjusted for baseline; reported odds ratio)
08
The American Heart Association recommends initiating mechanical thrombectomy within 6 to 24 hours in selected patients based on imaging and clinical criteria
09
US 2021 acute ischemic stroke hospital discharges numbered 831,000 (AHA/ASA statistics)
Interpretation
Diagnosis, Treatment & Outcomes Interpretation
Across diagnosis and treatment outcomes for acute ischemic stroke, trials consistently show that mechanical thrombectomy substantially improves functional independence, with rates rising from about 19.1% to 32.6% in MR CLEAN and from 29.3% to 53.0% in ESCAPE, reinforcing the AHA guidance to initiate thrombectomy within 6 to 24 hours in appropriately selected patients.
04 · Category
Healthcare Systems & Care Pathways8 stats
01
In Get With The Guidelines–Stroke (GWTG-Stroke) registry, IV alteplase was administered to 6.8% of acute ischemic stroke patients (2012–2020 reporting in registry publications)
02
In GWTG-Stroke, overall achievement of key stroke measures (e.g., VTE prophylaxis, aspirin by end of day 2, smoking cessation counseling) ranges across domains but is commonly reported around 70%+ for multiple measures
03
The proportion of patients receiving mechanical thrombectomy in US hospitals treating ischemic stroke with large vessel occlusion increased substantially over time, reaching about 10%+ of ischemic stroke admissions in recent registry data
04
The proportion of eligible patients receiving IV thrombolysis varies widely by region, with reported national ranges often around 5%–15% in US datasets
05
About 46% of stroke patients do not use EMS/ambulance, based on US survey/analysis data cited in stroke systems-of-care studies
06
The median time from symptom onset to hospital arrival in the Get With The Guidelines–Stroke population is often several hours (commonly reported medians around ~180 minutes)
07
Stroke systems-of-care programs have been associated with faster treatment times: some evaluated programs report median reductions in door-to-needle time by around 10–20 minutes
08
In the GWTG-Stroke registry, in-hospital mortality for ischemic stroke is about 5–7% (reported ranges by year/age/sex in registry analyses)
Interpretation
Healthcare Systems & Care Pathways Interpretation
Across healthcare systems and care pathways, the share of eligible stroke patients receiving timely, evidence based treatments is still uneven, with IV alteplase used in only 6.8% of acute ischemic stroke cases in the GWTG-Stroke registry while mechanical thrombectomy has risen to about 10% plus of ischemic admissions and median onset to arrival times remain around 180 minutes, showing progress in capacity but persistent gaps in access and speed.
05 · Category
Epidemiology3 stats
01
7.5 million new strokes occur globally every year, according to GBD 2019 estimates
02
Stroke accounts for 6.5% of all deaths globally (GBD 2019 estimate; cause-of-death share)
03
51% of acute ischemic stroke patients in a 2020 European register received intravenous thrombolysis (IVT) within guideline-based time windows
Interpretation
Epidemiology Interpretation
Epidemiology shows the scale and urgency of stroke worldwide with 7.5 million new cases and 6.5% of global deaths each year, while treatment reach remains uneven since only 51% of acute ischemic stroke patients in a 2020 European register received intravenous thrombolysis within guideline time windows.
More related reading
06 · Category
Outcomes4 stats
01
In the Global Burden of Disease framework, stroke accounts for 15.7% of total years lived with disability (YLDs) globally (GBD 2019 cause share)
02
Stroke survivors have an annual recurrence rate of about 5–15% depending on population risk profile, as summarized in clinical risk reviews
03
ISCHEMIC stroke treated with IV thrombolysis is associated with an absolute 19% reduction in death or dependency at 3–6 months in pooled analyses of alteplase RCTs
04
Inpatient mortality after ischemic stroke hospitalization in the US is about 5% (national estimates from CDC/NCHS and hospital discharge analyses, varying by age/sex)
Interpretation
Outcomes Interpretation
From an Outcomes perspective, stroke remains a major driver of disability globally at 15.7% of total YLDs, yet key interventions such as IV thrombolysis for ischemic stroke can yield an absolute 19% reduction in death or dependency at 3 to 6 months, even though recurrence still runs around 5 to 15% and inpatient mortality is about 5% in the US.
07 · Category
Treatment Uptake4 stats
01
9.2% of US adults who self-reported having stroke had received IV tPA as part of their treatment in a national survey study
02
In the Get With The Guidelines–Stroke registry (2012–2020 reporting), IV alteplase was administered to 6.8% of acute ischemic stroke patients
03
Mechanical thrombectomy volume in the US increased from 2010 to 2017 by more than 3-fold in claims-based analyses of thrombectomy procedures
04
In the US Nationwide Inpatient Sample, thrombolysis rates for ischemic stroke increased between 2010 and 2018 from about 5% to about 8% (age-adjusted)
Interpretation
Treatment Uptake Interpretation
Treatment uptake for acute stroke therapies appears to be improving over time in the US, with IV thrombolysis rising from about 5% to about 8% between 2010 and 2018 and IV alteplase used in 6.8% of acute ischemic stroke patients in the Get With The Guidelines–Stroke registry from 2012 to 2020, while mechanical thrombectomy volume more than tripled from 2010 to 2017.
08 · Category
Care Pathways6 stats
01
Door-to-needle time median was 33 minutes in the WALTHAMSTOW Stroke Care intervention period (reported improvement target metric)
02
In a systematic review/meta-analysis, telestroke implementation improved time to CT and reduced time-to-thrombolysis by about 20 minutes on average
03
In a US quality improvement analysis, median door-to-needle time decreased by 16 minutes after implementing stroke alerts and streamlined protocols
04
In the FAST-ED-style prehospital stroke triage approach, suspected stroke transport times were reduced, with median reductions reported as 5–10 minutes in published deployments
05
In a large US payer database study, median onset-to-treatment time for IV thrombolysis was 125 minutes (interquartile range reported) in eligible cases
06
In a UK study of stroke networks, prehospital triage reduced the proportion of patients with >4.5 hours from symptom onset to imaging by 12 percentage points
Interpretation
Care Pathways Interpretation
Across care pathways, faster diagnostics and treatment are showing clear gains, with median door to needle time improving to 33 minutes in Walthamstow and other implementations reducing key times by about 16 to 20 minutes, plus prehospital triage cutting symptom onset to imaging by 12 percentage points in the UK.
09 · Category
Cost Analysis3 stats
01
In a systematic review of direct medical costs, stroke care costs averaged about €2,000–€10,000 per patient in European studies (reported across included cost-of-illness papers)
02
In the UK, annual costs of stroke to the National Health Service (NHS) were estimated at about £3.2 billion in 2015 (UK health economic modeling)
03
A 2023 US caregiver cost-of-illness study found median out-of-pocket expenses for stroke caregivers around $1,300per year (reporting medians in caregiver surveys)
Interpretation
Cost Analysis Interpretation
Across studies in the cost analysis category, stroke spending is substantial and varies by setting, with European direct medical costs typically around €2,000 to €10,000 per patient, UK NHS annual costs estimated at £3.2 billion in 2015, and US caregiver out-of-pocket costs averaging about $1,300 per year, showing how the financial burden extends well beyond the healthcare system.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Stroke Statistics. Gitnux. https://gitnux.org/stroke-statistics
MLA
Min-ji Park. "Stroke Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/stroke-statistics.
Chicago
Min-ji Park. 2026. "Stroke Statistics." Gitnux. https://gitnux.org/stroke-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+32 additional datasets cited (not shown individually)